Table 1. Demographic characteristics.

Parameters	All	Smoker	Non-smoker	p value *	Male	Female	p value $
	(n = 151)	(n = 40)	(n = 111$)		(n = 71)	(n = 80)
Age (y/o)	41.3±12.1	40.8±12.6	41.5±12.0	0.914	40.1±11.9	42.4±12.1	0.350
OLZ dose (mg)	14.2±5.4	15.5±5.4	13.7±5.4	0.063	14.5±5.7	13.9±5.2	0.454
Weight (kg)	68.1±15.1	71.6±14.5	66.8±15.1	0.050	72.9±15.8	63.8±13.0	<0.001
BMI (kg/m2)	25.9±6.4	26.0±9.0	25.9±5.2	0.372	26.1±7.7	25.8±4.9	0.729
PANSS, Total	57.2±16.4	58.4±15.7	56.8±16.7	0.467	57.6±15.8	56.8±17.0	0.645
Positive	15.2±5.3	15.3±4.3	15.1±5.6	0.775	15±5.3	15.3±5.4	0.551
Negative	15.0±5.8	15.7±6.0	14.8±5.7	0.297	15.7±5.9	14.3±5.6	0.098
General	27.0±8.2	27.4±8.2	26.9±8.2	0.707	26.9±7.6	27.2±8.7	0.982
DMO level (ng/mL)	6.9±4.7	7.6±6.3	6.6±4.0	0.763	7.4±5.7	6.4±3.7	0.505
OLZ level (ng/mL)	37.0±25.6	27.0±23.1	40.5±25.6	0.004	29.3±24.0	43.8±25.1	<0.001
DMO C/D (ng/mL/mg)	0.6±0.4	0.5±0.4	0.6±0.4	0.559	0.6±0.4	0.5±0.4	0.376
OLZ C/D (ng/mL/mg)	2.9±2.3	1.7±1.2	3.3±2.5	<0.001	2.1±1.7	3.5±2.6	<0.001
Ratio of OLZ/DMO	7.0±6.16	4.8±4.1	7.85±6.4	0.005	5.4±4.9	8.6±6.6	<0.001

Abbreviations: OLZ, olanzapine; DMO, N-desmethyl-olanzapine; BMI, body mass index

*smoker vs. nonsmoker;

^$female vs. male;

p value was set at 0.05; an independent t-test was used for age, and a Mann-Whitney U-test was used for all other comparisons.